These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 8694537)

  • 1. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
    Ebert W; Muley T; Drings P
    Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
    Ebert W; Hoppe M; Muley T; Drings P
    Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
    Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
    Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC.
    Muley T; Dienemann H; Ebert W
    Anticancer Res; 2003; 23(5b):4085-93. PubMed ID: 14666606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
    Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
    Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
    Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy.
    Ebert W; Muley T
    Anticancer Res; 1999; 19(4A):2669-72. PubMed ID: 10470217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
    Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The importance of the tumor marker CYFRA 21-1 in patients with lung cancer after surgery or chemotherapy].
    Zissimopoulos A; Stellos K; Permenopoulou V; Petrakis G; Theodorakopoulos P; Baziotis N; Thalassinos N
    Hell J Nucl Med; 2007; 10(1):62-6. PubMed ID: 17450257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
    Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
    Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer.
    Chantapet P; Riantawan P; Lebnak P; Getngern P
    J Med Assoc Thai; 2000 Apr; 83(4):383-91. PubMed ID: 10808698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYFRA 21-1 in non-small cell lung cancer--standardisation and application during diagnosis.
    Pavićević R; Bubanović G; Franjević A; Stancić-Rokotov D; Samarzija M
    Coll Antropol; 2008 Jun; 32(2):485-98. PubMed ID: 18756899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients.
    Muley T; Dienemann H; Ebert W
    Anticancer Res; 2004; 24(3b):1953-6. PubMed ID: 15274383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of serum CYFRA 21-1 in lung cancer.
    Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S
    Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer.
    Schneider J; Velcovsky HG; Morr H; Katz N; Neu K; Eigenbrodt E
    Anticancer Res; 2000; 20(6D):5053-8. PubMed ID: 11326667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
    Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
    Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.